25 XP   0   0   10

Genfit
Buy, Hold or Sell?

Let's analyse Genfit together

PenkeI guess you are interested in Genfit. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Genfit. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Genfit

I send you an email if I find something interesting about Genfit.

Quick analysis of Genfit (30 sec.)










What can you expect buying and holding a share of Genfit? (30 sec.)

How much money do you get?

How much money do you get?
€0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
€1.90
Expected worth in 1 year
€0.92
How sure are you?
50.0%

+ What do you gain per year?

Total Gains per Share
€-0.98
Return On Investment
-29.5%

For what price can you sell your share?

Current Price per Share
€3.32
Expected price per share
€3.13 - €3.83
How sure are you?
50%

1. Valuation of Genfit (5 min.)




Live pricePrice per Share (EOD)

€3.32

Intrinsic Value Per Share

€-11.27 - €-8.21

Total Value Per Share

€-9.37 - €-6.31

2. Growth of Genfit (5 min.)




Is Genfit growing?

Current yearPrevious yearGrowGrow %
How rich?$102.2m$128.8m-$26.5m-26.0%

How much money is Genfit making?

Current yearPrevious yearGrowGrow %
Making money-$25.6m$72.7m-$98.4m-383.6%
Net Profit Margin-117.5%84.0%--

How much money comes from the company's main activities?

3. Financial Health of Genfit (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#379 / 1031

Most Revenue
#203 / 1031

Most Profit
#796 / 1031

Most Efficient
#608 / 1031

What can you expect buying and holding a share of Genfit? (5 min.)

Welcome investor! Genfit's management wants to use your money to grow the business. In return you get a share of Genfit.

What can you expect buying and holding a share of Genfit?

First you should know what it really means to hold a share of Genfit. And how you can make/lose money.

Speculation

The Price per Share of Genfit is €3.32. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Genfit.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Genfit, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is €1.90. Based on the TTM, the Book Value Change Per Share is €-0.24 per quarter. Based on the YOY, the Book Value Change Per Share is €2.47 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is €0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Genfit.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 % of Price per Share% of Price per Share% of Price per Share% of Price per Share% of Price per Share
Usd Eps-0.51-15.5%-0.51-15.5%1.3139.4%-0.91-27.4%-0.75-22.6%
Usd Book Value Change Per Share-0.26-8.0%-0.26-8.0%2.6780.3%-0.04-1.3%0.195.7%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.26-8.0%-0.26-8.0%2.6780.3%-0.04-1.3%0.195.7%
Usd Price Per Share4.29-4.29-4.67-10.23-18.54-
Price to Earnings Ratio-8.34--8.34-3.57--6.22--32.37-
Price-to-Total Gains Ratio-16.22--16.22-1.75--2.58--4.53-
Price to Book Ratio2.09-2.09-2.02-8.71-14.98-
Price-to-Total Gains Ratio-16.22--16.22-1.75--2.58--4.53-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share3.591244
Number of shares278
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.26-0.04
Usd Total Gains Per Share-0.26-0.04
Gains per Quarter (278 shares)-73.58-11.71
Gains per Year (278 shares)-294.32-46.83
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-294-3040-47-57
20-589-5980-94-104
30-883-8920-140-151
40-1177-11860-187-198
50-1472-14800-234-245
60-1766-17740-281-292
70-2060-20680-328-339
80-2355-23620-375-386
90-2649-26560-421-433
100-2943-29500-468-480

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.01.00.00.0%1.02.00.033.3%1.04.00.020.0%1.09.00.010.0%5.015.00.025.0%
Book Value Change Per Share0.01.00.00.0%1.02.00.033.3%2.03.00.040.0%5.05.00.050.0%10.010.00.050.0%
Dividend per Share0.00.01.00.0%0.00.03.00.0%0.00.05.00.0%0.00.010.00.0%0.00.020.00.0%
Total Gains per Share0.01.00.00.0%1.02.00.033.3%2.03.00.040.0%5.05.00.050.0%10.010.00.050.0%

Fundamentals of Genfit

About Genfit

Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2 trial to treat patients with cholangiocarcinoma (CCA); and VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.

Fundamental data was last updated by Penke on 2024-03-18 23:26:02.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Genfit.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Genfit earns for each €1 of revenue.

  • Above 10% is considered healthy but always compare Genfit to the Biotechnology industry mean.
  • A Net Profit Margin of -117.5% means that €-1.17 for each €1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Genfit:

  • The MRQ is -117.5%. The company is making a huge loss. -2
  • The TTM is -117.5%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-117.5%TTM-117.5%0.0%
TTM-117.5%YOY84.0%-201.5%
TTM-117.5%5Y-25,744.8%+25,627.4%
5Y-25,744.8%10Y-19,521.5%-6,223.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-117.5%-171.8%+54.3%
TTM-117.5%-205.8%+88.3%
YOY84.0%-262.1%+346.1%
5Y-25,744.8%-455.6%-25,289.2%
10Y-19,521.5%-589.0%-18,932.5%
1.1.2. Return on Assets

Shows how efficient Genfit is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Genfit to the Biotechnology industry mean.
  • -11.0% Return on Assets means that Genfit generated €-0.11 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Genfit:

  • The MRQ is -11.0%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -11.0%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-11.0%TTM-11.0%0.0%
TTM-11.0%YOY23.9%-34.9%
TTM-11.0%5Y-18.8%+7.7%
5Y-18.8%10Y-22.2%+3.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-11.0%-12.5%+1.5%
TTM-11.0%-12.2%+1.2%
YOY23.9%-11.2%+35.1%
5Y-18.8%-13.4%-5.4%
10Y-22.2%-14.7%-7.5%
1.1.3. Return on Equity

Shows how efficient Genfit is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Genfit to the Biotechnology industry mean.
  • -25.1% Return on Equity means Genfit generated €-0.25 for each €1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Genfit:

  • The MRQ is -25.1%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -25.1%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-25.1%TTM-25.1%0.0%
TTM-25.1%YOY56.5%-81.6%
TTM-25.1%5Y-85.2%+60.1%
5Y-85.2%10Y-65.1%-20.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-25.1%-15.8%-9.3%
TTM-25.1%-15.7%-9.4%
YOY56.5%-13.9%+70.4%
5Y-85.2%-18.3%-66.9%
10Y-65.1%-19.2%-45.9%

1.2. Operating Efficiency of Genfit.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Genfit is operating .

  • Measures how much profit Genfit makes for each €1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Genfit to the Biotechnology industry mean.
  • An Operating Margin of -136.4% means the company generated €-1.36  for each €1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Genfit:

  • The MRQ is -136.4%. The company is operating very inefficient. -2
  • The TTM is -136.4%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-136.4%TTM-136.4%0.0%
TTM-136.4%YOY95.8%-232.3%
TTM-136.4%5Y-22,219.7%+22,083.2%
5Y-22,219.7%10Y-17,600.3%-4,619.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-136.4%-299.1%+162.7%
TTM-136.4%-210.1%+73.7%
YOY95.8%-279.7%+375.5%
5Y-22,219.7%-459.9%-21,759.8%
10Y-17,600.3%-596.9%-17,003.4%
1.2.2. Operating Ratio

Measures how efficient Genfit is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 2.36 means that the operating costs are €2.36 for each €1 in net sales.

Let's take a look of the Operating Ratio trends of Genfit:

  • The MRQ is 2.364. The company is inefficient in keeping operating costs low. -1
  • The TTM is 2.364. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ2.364TTM2.3640.000
TTM2.364YOY0.603+1.761
TTM2.3645Y223.326-220.962
5Y223.32610Y177.207+46.119
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.3642.861-0.497
TTM2.3643.193-0.829
YOY0.6033.615-3.012
5Y223.3265.560+217.766
10Y177.2077.396+169.811

1.3. Liquidity of Genfit.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Genfit is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 4.02 means the company has €4.02 in assets for each €1 in short-term debts.

Let's take a look of the Current Ratio trends of Genfit:

  • The MRQ is 4.025. The company is very able to pay all its short-term debts. +2
  • The TTM is 4.025. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ4.025TTM4.0250.000
TTM4.025YOY4.267-0.242
TTM4.0255Y5.296-1.271
5Y5.29610Y6.497-1.201
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ4.0253.986+0.039
TTM4.0254.440-0.415
YOY4.2675.552-1.285
5Y5.2966.158-0.862
10Y6.4976.492+0.005
1.3.2. Quick Ratio

Measures if Genfit is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Genfit to the Biotechnology industry mean.
  • A Quick Ratio of 4.09 means the company can pay off €4.09 for each €1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Genfit:

  • The MRQ is 4.090. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 4.090. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ4.090TTM4.0900.000
TTM4.090YOY4.221-0.131
TTM4.0905Y5.269-1.179
5Y5.26910Y4.818+0.450
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ4.0903.638+0.452
TTM4.0904.168-0.078
YOY4.2215.515-1.294
5Y5.2696.012-0.743
10Y4.8186.209-1.391

1.4. Solvency of Genfit.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Genfit assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Genfit to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.56 means that Genfit assets are financed with 56.1% credit (debt) and the remaining percentage (100% - 56.1%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Genfit:

  • The MRQ is 0.561. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.561. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.561TTM0.5610.000
TTM0.561YOY0.577-0.016
TTM0.5615Y0.772-0.210
5Y0.77210Y0.554+0.217
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.5610.335+0.226
TTM0.5610.330+0.231
YOY0.5770.267+0.310
5Y0.7720.367+0.405
10Y0.5540.378+0.176
1.4.2. Debt to Equity Ratio

Measures if Genfit is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Genfit to the Biotechnology industry mean.
  • A Debt to Equity ratio of 128.0% means that company has €1.28 debt for each €1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Genfit:

  • The MRQ is 1.280. The company is able to pay all its debts with equity. +1
  • The TTM is 1.280. The company is able to pay all its debts with equity. +1
Trends
Current periodCompared to+/- 
MRQ1.280TTM1.2800.000
TTM1.280YOY1.365-0.085
TTM1.2805Y3.058-1.778
5Y3.05810Y1.881+1.177
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.2800.376+0.904
TTM1.2800.398+0.882
YOY1.3650.334+1.031
5Y3.0580.429+2.629
10Y1.8810.476+1.405

2. Market Valuation of Genfit

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every €1 in earnings Genfit generates.

  • Above 15 is considered overpriced but always compare Genfit to the Biotechnology industry mean.
  • A PE ratio of -8.34 means the investor is paying €-8.34 for every €1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Genfit:

  • The EOD is -6.976. Based on the earnings, the company is expensive. -2
  • The MRQ is -8.337. Based on the earnings, the company is expensive. -2
  • The TTM is -8.337. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-6.976MRQ-8.337+1.361
MRQ-8.337TTM-8.3370.000
TTM-8.337YOY3.569-11.906
TTM-8.3375Y-6.222-2.115
5Y-6.22210Y-32.370+26.148
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-6.976-2.643-4.333
MRQ-8.337-2.418-5.919
TTM-8.337-2.742-5.595
YOY3.569-4.123+7.692
5Y-6.222-6.257+0.035
10Y-32.370-6.478-25.892
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Genfit:

  • The EOD is -2.278. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -2.722. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -2.722. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-2.278MRQ-2.722+0.445
MRQ-2.722TTM-2.7220.000
TTM-2.722YOY2.415-5.138
TTM-2.7225Y-6.939+4.217
5Y-6.93910Y-35.966+29.027
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-2.278-3.244+0.966
MRQ-2.722-2.939+0.217
TTM-2.722-3.478+0.756
YOY2.415-5.592+8.007
5Y-6.939-8.473+1.534
10Y-35.966-8.881-27.085
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Genfit is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 2.09 means the investor is paying €2.09 for each €1 in book value.

Let's take a look of the Price to Book Ratio trends of Genfit:

  • The EOD is 1.750. Based on the equity, the company is underpriced. +1
  • The MRQ is 2.092. Based on the equity, the company is underpriced. +1
  • The TTM is 2.092. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD1.750MRQ2.092-0.342
MRQ2.092TTM2.0920.000
TTM2.092YOY2.015+0.077
TTM2.0925Y8.711-6.619
5Y8.71110Y14.980-6.269
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD1.7502.124-0.374
MRQ2.0922.041+0.051
TTM2.0922.118-0.026
YOY2.0152.915-0.900
5Y8.7113.682+5.029
10Y14.9804.114+10.866
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Genfit compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.245-0.2450%2.466-110%-0.039-84%0.176-239%
Book Value Per Share--1.8971.8970%2.142-11%1.164+63%1.359+40%
Current Ratio--4.0254.0250%4.267-6%5.296-24%6.497-38%
Debt To Asset Ratio--0.5610.5610%0.577-3%0.772-27%0.554+1%
Debt To Equity Ratio--1.2801.2800%1.365-6%3.058-58%1.881-32%
Dividend Per Share----0%-0%-0%-0%
Eps---0.476-0.4760%1.209-139%-0.840+77%-0.693+46%
Free Cash Flow Per Share---1.458-1.4580%1.787-182%-0.761-48%-0.628-57%
Free Cash Flow To Equity Per Share---1.534-1.5340%1.627-194%-0.398-74%0.323-575%
Gross Profit Margin--1.0421.0420%0.977+7%1.068-2%1.034+1%
Intrinsic Value_10Y_max---8.209--------
Intrinsic Value_10Y_min---11.268--------
Intrinsic Value_1Y_max---0.603--------
Intrinsic Value_1Y_min---0.862--------
Intrinsic Value_3Y_max---1.979--------
Intrinsic Value_3Y_min---2.838--------
Intrinsic Value_5Y_max---3.557--------
Intrinsic Value_5Y_min---5.068--------
Market Cap165452200.000-20%197745280.000197745280.0000%240028444.344-18%476188008.869-58%856446684.434-77%
Net Profit Margin---1.175-1.1750%0.840-240%-257.448+21819%-195.215+16520%
Operating Margin---1.364-1.3640%0.958-242%-222.197+16188%-176.003+12802%
Operating Ratio--2.3642.3640%0.603+292%223.326-99%177.207-99%
Pb Ratio1.750-20%2.0922.0920%2.015+4%8.711-76%14.980-86%
Pe Ratio-6.976+16%-8.337-8.3370%3.569-334%-6.222-25%-32.370+288%
Price Per Share3.320-20%3.9683.9680%4.316-8%9.455-58%17.136-77%
Price To Free Cash Flow Ratio-2.278+16%-2.722-2.7220%2.415-213%-6.939+155%-35.966+1221%
Price To Total Gains Ratio-13.568+16%-16.217-16.2170%1.750-1026%-2.580-84%-4.530-72%
Quick Ratio--4.0904.0900%4.221-3%5.269-22%4.818-15%
Return On Assets---0.110-0.1100%0.239-146%-0.188+70%-0.222+102%
Return On Equity---0.251-0.2510%0.565-144%-0.852+239%-0.651+159%
Total Gains Per Share---0.245-0.2450%2.466-110%-0.039-84%0.176-239%
Usd Book Value--102250937.600102250937.6000%128827224.900-21%65435710.780+56%74575751.270+37%
Usd Book Value Change Per Share---0.265-0.2650%2.667-110%-0.042-84%0.190-239%
Usd Book Value Per Share--2.0522.0520%2.316-11%1.259+63%1.470+40%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.515-0.5150%1.308-139%-0.909+77%-0.750+46%
Usd Free Cash Flow---78572524.600-78572524.6000%107497182.600-173%-38781108.400-51%-32719391.404-58%
Usd Free Cash Flow Per Share---1.577-1.5770%1.933-182%-0.823-48%-0.679-57%
Usd Free Cash Flow To Equity Per Share---1.659-1.6590%1.760-194%-0.431-74%0.349-575%
Usd Market Cap178969644.740-20%213901069.376213901069.3760%259638768.247-18%515092569.193-58%926418378.553-77%
Usd Price Per Share3.591-20%4.2924.2920%4.669-8%10.228-58%18.536-77%
Usd Profit---25657924.000-25657924.0000%72754060.300-135%-43775966.320+71%-36932656.172+44%
Usd Revenue--21844931.50021844931.5000%86610637.300-75%28543250.580-23%14752192.149+48%
Usd Total Gains Per Share---0.265-0.2650%2.667-110%-0.042-84%0.190-239%
 EOD+3 -5MRQTTM+0 -0YOY+6 -285Y+16 -1810Y+16 -18

3.2. Fundamental Score

Let's check the fundamental score of Genfit based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-6.976
Price to Book Ratio (EOD)Between0-11.750
Net Profit Margin (MRQ)Greater than0-1.175
Operating Margin (MRQ)Greater than0-1.364
Quick Ratio (MRQ)Greater than14.090
Current Ratio (MRQ)Greater than14.025
Debt to Asset Ratio (MRQ)Less than10.561
Debt to Equity Ratio (MRQ)Less than11.280
Return on Equity (MRQ)Greater than0.15-0.251
Return on Assets (MRQ)Greater than0.05-0.110
Total3/10 (30.0%)

3.3. Technical Score

Let's check the technical score of Genfit based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5052.155
Ma 20Greater thanMa 503.238
Ma 50Greater thanMa 1003.390
Ma 100Greater thanMa 2003.340
OpenGreater thanClose3.310
Total2/5 (40.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2018-12-312019-12-312020-12-312021-12-312022-12-31
Total Other Income Expense Net -10,3912,502-7,889-15,969-23,85816,594-7,26410,9773,713



Latest Balance Sheet

Balance Sheet of 2022-12-31. Currency in EUR. All numbers in thousands.

Summary
Total Assets215,540
Total Liabilities121,012
Total Stockholder Equity94,528
 As reported
Total Liabilities 121,012
Total Stockholder Equity+ 94,528
Total Assets = 215,540

Assets

Total Assets215,540
Total Current Assets158,459
Long-term Assets57,081
Total Current Assets
Cash And Cash Equivalents 136,001
Short-term Investments 4,550
Net Receivables 15,906
Inventory 4
Other Current Assets 1,998
Total Current Assets  (as reported)158,459
Total Current Assets  (calculated)158,459
+/-0
Long-term Assets
Property Plant Equipment 8,210
Long Term Investments 4,914
Intangible Assets 43,957
Other Assets 1,297
Long-term Assets  (as reported)57,081
Long-term Assets  (calculated)58,378
+/- 1,297

Liabilities & Shareholders' Equity

Total Current Liabilities39,370
Long-term Liabilities81,642
Total Stockholder Equity94,528
Total Current Liabilities
Short-term Debt 5,080
Short Long Term Debt 5,080
Accounts payable 14,845
Other Current Liabilities 4,966
Total Current Liabilities  (as reported)39,370
Total Current Liabilities  (calculated)29,971
+/- 9,399
Long-term Liabilities
Long term Debt Total 70,195
Capital Lease Obligations 6,559
Long-term Liabilities Other 1
Long-term Liabilities  (as reported)81,642
Long-term Liabilities  (calculated)76,755
+/- 4,887
Total Stockholder Equity
Common Stock12,459
Retained Earnings -361,269
Accumulated Other Comprehensive Income -1,344
Capital Surplus 444,683
Total Stockholder Equity (as reported)94,528
Total Stockholder Equity (calculated)94,529
+/- 1
Other
Capital Stock12,459
Cash And Equivalents119,091
Cash and Short Term Investments 140,551
Common Stock Shares Outstanding 49,415
Current Deferred Revenue14,479
Liabilities and Stockholders Equity 215,540
Net Debt -60,726
Net Invested Capital 169,803
Net Working Capital 119,089
Property Plant and Equipment Gross 20,794
Short Long Term Debt Total 75,275



Balance Sheet

Currency in EUR. All numbers in thousands.

 Trend2022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-312011-12-312010-12-312009-12-312008-12-312007-12-312006-12-312005-12-312004-12-312003-12-31
> Total Assets 
26,136
28,156
30,835
46,244
40,214
45,992
38,428
31,387
29,076
23,581
29,151
86,366
69,258
166,214
293,183
229,478
309,853
198,614
281,720
215,540
215,540281,720198,614309,853229,478293,183166,21469,25886,36629,15123,58129,07631,38738,42845,99240,21446,24430,83528,15626,136
   > Total Current Assets 
0
0
0
0
0
28,958
0
19,696
19,160
0
27,099
83,813
66,753
161,996
283,572
218,116
290,753
184,717
268,097
158,459
158,459268,097184,717290,753218,116283,572161,99666,75383,81327,099019,16019,696028,95800000
       Cash And Cash Equivalents 
0
11,837
12,498
22,373
15,828
16,871
17,434
13,942
12,805
6,304
20,922
76,005
60,111
152,277
273,820
207,240
276,748
171,029
258,756
136,001
136,001258,756171,029276,748207,240273,820152,27760,11176,00520,9226,30412,80513,94217,43416,87115,82822,37312,49811,8370
       Short-term Investments 
0
1,577
1,682
1,502
1,549
921
0
0
14
18
0
4,008
22
174
31
0
0
0
-785
4,550
4,550-78500031174224,00801814009211,5491,5021,6821,5770
       Net Receivables 
5,664
5,548
2,822
4,543
4,775
10,602
5,329
4,793
733
3,983
4,951
6,703
5,998
8,394
7,956
8,793
12,033
11,919
7,236
15,906
15,9067,23611,91912,0338,7937,9568,3945,9986,7034,9513,9837334,7935,32910,6024,7754,5432,8225,5485,664
       Inventory 
35
37
28
31
31
39
208
187
173
158
167
248
28
14
4
4
4
4
4
4
4444441428248167158173187208393131283735
   > Long-term Assets 
0
0
0
0
0
17,034
0
11,691
9,916
0
2,052
2,553
0
4,219
9,611
11,362
19,099
13,897
13,623
57,081
57,08113,62313,89719,09911,3629,6114,21902,5532,05209,91611,691017,03400000
       Property Plant Equipment 
9,592
8,312
10,017
9,897
9,382
9,576
9,160
8,375
7,641
9,401
1,000
1,333
1,324
3,010
6,324
7,764
16,453
11,648
9,015
8,210
8,2109,01511,64816,4537,7646,3243,0101,3241,3331,0009,4017,6418,3759,1609,5769,3829,89710,0178,3129,592
       Goodwill 
156
128
32
75
75
75
75
75
75
75
75
75
0
0
0
0
0
0
0
0
0000000075757575757575757532128156
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
300
0
109
267
770
1,023
1,458
4,431
4,914
4,9144,4311,4581,023770267109030000000000000
       Intangible Assets 
323
239
221
344
316
308
181
105
75
106
56
86
563
667
636
795
920
791
174
43,957
43,957174791920795636667563865610675105181308316344221239323
       Long-term Assets Other 
0
0
0
0
0
3,024
0
1,253
2,008
0
681
776
7
0
2,384
2,033
-1
-11,945
3
-55,784
-55,7843-11,945-12,0332,3840777668102,0081,25303,02400000
> Total Liabilities 
17,091
17,565
17,448
18,473
14,846
23,610
22,908
22,998
24,619
16,747
15,058
15,937
13,842
23,417
188,954
208,539
225,788
214,776
162,623
121,012
121,012162,623214,776225,788208,539188,95423,41713,84215,93715,05816,74724,61922,99822,90823,61014,84618,47317,44817,56517,091
   > Total Current Liabilities 
4,204
5,196
7,496
9,407
7,430
14,112
9,555
11,806
10,886
8,495
9,075
10,391
8,613
17,562
27,106
39,248
43,495
31,067
62,837
39,370
39,37062,83731,06743,49539,24827,10617,5628,61310,3919,0758,49510,88611,8069,55514,1127,4309,4077,4965,1964,204
       Short-term Debt 
0
0
0
0
0
921
0
0
14
18
2,176
1,638
1,199
1,170
3,163
3,154
4,377
4,348
2,188
5,080
5,0802,1884,3484,3773,1543,1631,1701,1991,6382,17618140092100000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
2,176
1,638
1,199
1,170
2,743
2,634
2,425
4,348
2,188
5,080
5,0802,1884,3482,4252,6342,7431,1701,1991,6382,1760000000000
       Accounts payable 
1,872
2,631
3,380
4,687
3,589
3,549
3,706
4,143
4,008
2,926
5,454
5,900
5,275
13,341
19,053
32,649
36,917
25,564
40,988
14,845
14,84540,98825,56436,91732,64919,05313,3415,2755,9005,4542,9264,0084,1433,7063,5493,5894,6873,3802,6311,872
       Other Current Liabilities 
1,243
1,311
3,003
3,928
3,124
3,740
2,942
2,704
3,701
3,804
2,888
3,584
239
370
4,889
3,444
2,062
1,031
5,363
4,966
4,9665,3631,0312,0623,4444,8893702393,5842,8883,8043,7012,7042,9423,7403,1243,9283,0031,3111,243
   > Long-term Liabilities 
0
0
0
0
0
9,499
0
11,192
0
0
5,983
5,546
0
5,855
161,848
169,291
182,293
183,709
99,786
81,642
81,64299,786183,709182,293169,291161,8485,85505,5465,9830011,19209,49900000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
5,004
158,288
163,202
175,852
178,114
72,047
70,195
70,19572,047178,114175,852163,202158,2885,0040000000000000
       Capital Lease Obligations Min Short Term Debt
0
0
0
0
0
-921
0
0
-14
-18
-2,176
-1,638
-1,199
-784
-1,274
-1,253
7,904
5,783
4,881
1,479
1,4794,8815,7837,904-1,253-1,274-784-1,199-1,638-2,176-18-1400-92100000
       Long-term Liabilities Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
849
1
1
0
0
2
1
1200118490000000000000
> Total Stockholder Equity
8,861
10,328
13,343
27,771
25,368
22,382
15,520
8,389
4,457
6,834
14,093
70,429
55,416
142,797
104,229
20,939
84,065
-16,162
119,097
94,528
94,528119,097-16,16284,06520,939104,229142,79755,41670,42914,0936,8344,4578,38915,52022,38225,36827,77113,34310,3288,861
   Common Stock
2,400
2,400
2,400
2,818
2,818
2,818
2,818
2,916
3,408
4,011
5,135
5,989
5,990
7,792
7,792
7,796
9,715
9,722
12,454
12,459
12,45912,4549,7229,7157,7967,7927,7925,9905,9895,1354,0113,4082,9162,8182,8182,8182,8182,4002,4002,400
   Retained Earnings 
2,580
1,486
1,773
328
0
-3,961
0
-9,381
-20,367
0
-35,668
-17,025
-17,135
-33,667
-161,135
-238,418
-303,484
-404,850
-337,817
-361,269
-361,269-337,817-404,850-303,484-238,418-161,135-33,667-17,135-17,025-35,6680-20,367-9,3810-3,96103281,7731,4862,580
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
237,305
251,932
251,554
377,821
379,057
444,438
444,683
444,683444,438379,057377,821251,554251,932237,3050000000000000
   Treasury Stock00-811-477-730-127-1270000000000000
   Other Stockholders Equity 
0
0
0
0
0
0
0
0
0
0
-22,705
-14
-51,350
-68,506
257,580
251,555
377,820
379,058
444,438
444,682
444,682444,438379,058377,820251,555257,580-68,506-51,350-14-22,7050000000000



Balance Sheet

Currency in EUR. All numbers in thousands.




Cash Flow

Currency in EUR. All numbers in thousands.




Income Statement

Currency in EUR. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue20,395
Cost of Revenue--
Gross Profit-20,395
 
Operating Income (+$)
Gross Profit-
Operating Expense--
Operating Income-0
 
Operating Expense (+$)
Research Development-
Selling General Administrative-
Selling And Marketing Expenses-
Operating Expense-0
 
Net Interest Income (+$)
Interest Income-
Interest Expense--
Other Finance Cost-0
Net Interest Income-
 
Pretax Income (+$)
Operating Income-
Net Interest Income-
Other Non-Operating Income Expenses-
Income Before Tax (EBT)-0
EBIT - interestExpense = 0
0
0
Interest Expense-
Earnings Before Interest and Taxes (EBIT)-0
Earnings Before Interest and Taxes (EBITDA)-
 
After tax Income (+$)
Income Before Tax-
Tax Provision--
Net Income From Continuing Ops-0
Net Income-
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net-0
 

Technical Analysis of Genfit
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Genfit. The general trend of Genfit is BEARISH with 14.3% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Genfit's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-14.3%) Bearish trend (14.3%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Genfit.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 3.41 < 3.78 < 3.83.

The bearish price targets are: 3.14 > 3.13 > 3.13.

Tweet this
Genfit Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Genfit. The current mas is .

The long score for the Moving Averages is 6/14.
The longshort score for the Moving Averages is -2/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Genfit Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Genfit. The current macd is -0.01753.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Genfit price going up in the near term. +2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Genfit. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Genfit price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Genfit Daily Moving Average Convergence/Divergence (MACD) ChartGenfit Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Genfit. The current adx is 12.35.

The long score for the Directional Movement Index (DMI) is 2/7.
The longshort score for the Directional Movement Index (DMI) is 2/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Genfit shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bullish trend could be forming. +1
Genfit Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Genfit. The current sar is 3.18300768.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Genfit Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Genfit. The current rsi is 52.15. The current phase is Correction in bear market.

The long score for the Relative Strength Index (RSI) is 4/13.
The longshort score for the Relative Strength Index (RSI) is 4/(-13 +13).

  • Correction in bear market: Extended price decline in a downtrend, significant pullback. Consider reducing exposure, wait for signs of trend reversal.
  • Trending up: The RSI is trending up. +1
Genfit Daily Relative Strength Index (RSI) ChartGenfit Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Genfit. The current phase is Correction in bear market.

The long score for the Stochastic Oscillator is 2/6.
The longshort score for the Stochastic Oscillator is 0/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Genfit price going down in the near term. -2
  • Trending up: The STOCH %K is trending up. +1
Genfit Daily Stochastic Oscillator ChartGenfit Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Genfit. The current cci is 147.75.

The long score for the Commodity Channel Index (CCI) is 1/1.
The longshort score for the Commodity Channel Index (CCI) is 1/(-1 +1).

  • CCI > 100: The CCI is above 100, it indicates that the price is significantly above its average, suggesting a potential overbought condition. +1
Genfit Daily Commodity Channel Index (CCI) ChartGenfit Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Genfit. The current cmo is 14.89.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Genfit Daily Chande Momentum Oscillator (CMO) ChartGenfit Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Genfit. The current willr is -21.73913043.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Genfit is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Genfit Daily Williams %R ChartGenfit Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Genfit.

Genfit Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Genfit. The current atr is 0.09945474.

Genfit Daily Average True Range (ATR) ChartGenfit Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Genfit. The current obv is 3,419,094.

Genfit Daily On-Balance Volume (OBV) ChartGenfit Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Genfit. The current mfi is 63.61.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Genfit Daily Money Flow Index (MFI) ChartGenfit Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Genfit.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-07STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-11-08CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-11-09WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-11-10STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-11-13STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-11-14STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-15CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-11-16SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2023-11-20STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-11-21STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-11-22WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-11-23MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2023-11-27CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-11-28STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-29STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-30STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-01STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-12-05STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-12-07SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-08MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-12STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-13STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-18STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-19RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2023-12-21SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-22STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-27MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-29STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-02SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-03CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-01-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-05ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-08MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-01-09CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-10SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-01-11DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-16STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-17STOCH SHORT EXITThe %K line crosses above the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-01-19STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-22DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-23SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-24MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-01-25STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-29STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-31STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-05MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-06STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-07DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-08SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-02-09WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-12DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-13STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-14STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-15STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-16STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-19STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-20CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-21DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-02-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-23STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-27STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-29BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-05STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-06STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-13SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-03-14MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-15MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-19MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-21STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-22STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-26STOCH LONG EXITThe %K line crosses below the %D line.

6.3. Candlestick Patterns

Genfit Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Genfit based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5052.155
Ma 20Greater thanMa 503.238
Ma 50Greater thanMa 1003.390
Ma 100Greater thanMa 2003.340
OpenGreater thanClose3.310
Total2/5 (40.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Genfit with someone you think should read this too:
  • Are you bullish or bearish on Genfit? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Genfit? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Genfit

I send you an email if I find something interesting about Genfit.


Comments

How you think about this?

Leave a comment

Stay informed about Genfit.

Receive notifications about Genfit in your mailbox!